"Das Universitätsklinikum Tulln ist ein Krankenhaus in Tulln an der Donau, Niederösterreich. Es befindet sich am Alten Ziegelweg 10 im Südosten der Stadt, verfügt über ca. 440 Betten und bildet zusammen mit dem Universitätsklinikum Krems und dem Universitätsklinikum St. Pölten die Universitätskliniken der 2013 gegründeten, in Krems an der Donau angesiedelten Karl Landsteiner Privatuniversität für Gesundheitswissenschaften."

During the past decade, Universitätsklinikum Tulln conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 1 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Tulln" #1 sponsor was "Austrian Breast & Colorectal Cancer Study Group" with 2 trials, followed by "Abbott Medical Devices" with 1 trials sponsored, "Karl Landsteiner University of Health Sciences" with 1 trials sponsored, "Medical University Innsbruck" with 1 trials sponsored and "St. Anna Kinderkrebsforschung" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Tulln" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Department of Internal Medicine, University Hospital Tulln, Alter Ziegelweg 10, 3430, Tulln, Austria" with 1 trials as a collaborator, "Department of Neurology, University Hospital Tulln, Alter Ziegelweg 10, 3430, Tulln, Austria" with 1 trials as a collaborator, "Novartis Pharmaceuticals" with 1 trials as a collaborator and "NÖ Landesgesundheitsagentur, legal entity of University Hospitals in Lower Austria" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Tulln" are "Atrial Fibrillation" (2 trials), "Breast Cancer" (1 trials), "Cardiac Arrhythmias" (1 trials), "Colon Cancer Stage II" (1 trials) and "Covid19" (1 trials). Many other conditions were trialed in "Universitätsklinikum Tulln" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Tulln" are "Drug" (5 trials), "Device" (1 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Confirm Rx ICM insertion procedure" (1 trials), "ECG monitoring" (1 trials), "Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)" (1 trials) and "Fluorouracil" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Tulln" are 7 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Universitätsklinikum Tulln". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Universitätsklinikum Tulln, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Tulln, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".